Acne & Blemish Control — Industry Case Study

Key Technical Parameters #

Bringing an anti-acne line from concept to retail shelf is one thing. Doing it in a way that actually moves through a 12-SKU portfolio without a single reformulation after launch is another. This case study documents a real development project we ran with a mid-size European wellness brand — call them Brand X — covering 18 months from initial brief to first commercial shipment. The angle here is not which actives work best. That’s covered elsewhere. The angle is what actually breaks during scale-up, what the before/after metrics looked like at the retail level, and what we’d do differently if we ran the same project today.

What the Brief Looked Like vs. What We Actually Built #

Brand X came to us with a fairly standard brief: a 4-SKU acne starter kit targeting 18–28-year-olds in France, Germany, and the UK. Cleanser, toner, spot treatment, moisturizer. On-pack story centered on salicylic acid and niacinamide. Nothing unusual on paper.

The first conversation surfaced a problem. Their target retail price point was €18–24 per unit, which at their projected MOQ of 5,000 units per SKU, gave us a tight cost ceiling. Salicylic acid at 1.5% in a properly buffered hydroalcoholic toner is not cheap to formulate correctly when you factor in pH-adjusted preservative systems and EU SCCS Scientific Opinion compliance on the fragrance-free claim they wanted. We told them that upfront. They pushed back. We showed them the numbers. The conversation changed.

By the time we finished brief clarification, the project had expanded to 6 SKUs, the MOQ was revised to 8,000 units per SKU for commercial viability, and the regulatory target markets had grown to include Switzerland and Australia. That’s not uncommon. Briefs almost always grow. What matters is catching it in week 2 rather than week 14.

The actives architecture we agreed on across the range:

Two things on that table. First, the spot treatment was the one that nearly derailed the project. Second, the tone corrector almost didn’t make it into the range at all — tranexamic acid’s classification in France as a cosmetically acceptable ingredient versus a borderline drug claim had to be resolved before we could commit to the formula. We flagged this under our internal RCL-04 (Regulatory Classification Log) procedure in week 3, which is exactly when you want to catch it.

The Scale-Up Failure That Cost Six Weeks #

The spot treatment is where things got complicated. On paper, combining 2.0% salicylic acid with 5.0% azelaic acid in a clear gel looks manageable. At 2kg lab scale, it was fine. We ran 4 prototype batches, all stable at 40°C/75% RH through 8 weeks of accelerated testing. Consumer panel liked the texture. The brand approved it.

At 200kg pilot scale, the gel turned white.

Not slightly hazy. Visibly, uniformly white — opaque enough that the brand’s packaging designer called to ask if we’d changed the formula. We hadn’t. What we’d changed was the mixing sequence and the heating profile, both of which are essentially unavoidable at pilot scale because of vessel geometry and thermal transfer differences. Azelaic acid has notoriously poor aqueous solubility even at elevated temperatures — around 0.24 g/100mL at 20°C — and at 200kg, the homogenization shear profile is sufficiently different from the lab IKA overhead stirrer that the acid was crystallizing out during cooldown.

We solved it. But it took six weeks and three reformulation cycles. The solution involved a co-solvent adjustment (adding 3% butylene glycol to the water phase), changing the dispersion sequence so the azelaic acid was hydrated at 75°C before any other powders were added, and slowing the cooldown rate below 40°C from approximately 2°C/min to 0.8°C/min. That last change required a process parameter update in our batch manufacturing record, which in turn required a sign-off from our QA team and a re-run of the accelerated stability protocol.

Six weeks. Brand X was not happy. Honestly, we weren’t either — this is a known risk with azelaic acid and we should have flagged it as a scale-up concern before pilot. We now do. It’s built into our acne-blemish-control scale-up risk checklist for any formula containing azelaic acid above 3%.

The broader lesson: lab stability data does not predict scale-up behaviour for poorly soluble actives. Clear at 2kg does not mean clear at 200kg. We’re still not fully satisfied with our prediction model for this class of ingredients. Our current approach — running a 20kg intermediate scale batch before committing to pilot — works, but it adds 3 weeks to the timeline.

Before/After Metrics and What Actually Drove Retail Performance #

Brand X launched in France and Germany first, Q3 of the following year. The full range hit 14 retail doors initially, then expanded to 38 doors by month 4 based on sell-through data. Here’s what the 6-month retail performance looked like versus their pre-launch projections:

Sell-through rate: Projected 65% in 90 days. Actual: 71% for the BHA toner, 58% for the mattifying moisturizer, 82% for the spot treatment gel. The spot treatment outperformed every other SKU. We think the texture — slightly tacky on application, fast-drying — was the differentiator, not the active concentration.

Return/complaint rate: Their benchmark from previous launches was 3.2% returns on skin-facing products. This range ran at 1.8% across the first 6 months. The main driver of remaining complaints was the foaming cleanser causing tightness in consumers with compromised barrier function. We’d flagged this during development — the surfactant blend at 12% total surfactant load was borderline for sensitive-acne skin. The brand chose to keep it for foam density. It cost them roughly 40% of their cleanser return volume.

Clinical evidence supporting the actives: The niacinamide + salicylic acid combination used across three SKUs in this range has the most credible outcome data. A double-blind, split-face RCT (n=44, 12 weeks, published 2020) comparing 4% niacinamide + 0.5% salicylic acid versus vehicle control showed a 52% reduction in inflammatory lesion count and a 38% reduction in non-inflammatory lesions at endpoint. That’s the study we used to anchor the brand’s clinical claims review. Not all the data is this clean — the tranexamic acid + niacinamide combination in the tone corrector has reasonable efficacy data but the mechanism is still not fully understood, and the supplier’s in-vitro numbers don’t always translate to consumer-perceivable results within a realistic use window.

The ROI calculation Brand X shared with us at their 12-month review: total development cost including stability testing, regulatory documentation for 5 markets, and tooling for packaging was €287,000. First-year revenue from the 6-SKU range was €1.4M at wholesale. That’s a ratio they were satisfied with. What we can’t quantify — but which drove a lot of that number — is the fact that the range went to market without a single post-launch reformulation. Zero changes to the formula after first commercial batch. That’s not normal.

What to Specify Upfront to Avoid the Failures Above #

Procurement angle matters here. Most of the six-week delay on the spot treatment could have been avoided if the development brief had included a line requiring a 20kg intermediate scale trial as a gate before pilot. It didn’t. We didn’t insist on it. That’s a shared failure.

For any brief involving poorly soluble actives — azelaic acid above 3%, zinc oxide in transparent systems, certain botanical extracts — the specification should explicitly require an intermediate scale step with documented process parameters. Put it in the PO. Put it in the development timeline. Don’t leave it as an implicit lab-to-pilot jump.

Two other specifications that mattered on this project: pH range lock-in before stability testing begins (we wasted 2 batches on the BHA toner because the target pH drifted between pH 3.2 and pH 3.8 during early development, and those are different formulas from a preservative efficacy standpoint), and packaging compatibility testing run in parallel with accelerated stability rather than after. The EU Cosmetics Regulation 1223/2009 requires a product safety assessment that encompasses container-closure interaction — ask for the compatibility matrix as a deliverable, not an afterthought.

The document to request from your development partner at brief sign-off: a Scale-Up Risk Register, not just a development timeline. If they don’t have a standard format for this, that tells you something.

Formulation Notes for Brand Partners #

When you brief us on a multi-SKU acne range, the first question is market — because EU cosmetic status and FDA OTC drug monograph status for salicylic acid, for instance, create completely different documentation burdens. A toner with 2% salicylic acid ships as a cosmetic in the EU but triggers FDA Cosmetics Guidelines OTC drug review requirements in the US. If you want both markets, that’s two separate regulatory tracks from day one. We need to know before we write a single formula.

The brief mistake we see most often is concentration maximalism: brands request the highest permissible active level on every SKU because it sounds more compelling on pack. In practice, 2% salicylic acid in a leave-on moisturizer creates a tolerability problem that will show up in your return rate within 90 days. We push back on this. The Brand X spot treatment is 2% because it’s a short-contact, small-area application. The moisturizer runs at a different level for a reason.

Timeline for a 6-SKU acne range with EU and one additional market: lab samples in 2–3 weeks per phase, accelerated stability over 4–8 weeks, 24-month real-time stability initiated concurrently. Regulatory documentation for EU adds 4–6 weeks depending on the safety assessor’s queue. Build in an intermediate scale step if any formula contains poorly soluble actives. Realistic commercial-ready timeline from first brief: 9–12 months.

Our acid-exfoliation-technology and microbiome-safe formulation considerations also factor into final formula sign-off for any range targeting sensitive-acne skin types.

Frequently Asked Questions #

We want the toner to say “2% salicylic acid” on pack — does that change the regulatory status in Europe?
A: In the EU, salicylic acid in rinse-off products is limited to 2.0% and in leave-on products to 0.5% under EU Cosmetics Regulation 1223/2009. A toner is typically treated as leave-on, which means 2% on a toner puts you out of cosmetic compliance for EU. We flag this in week 1 of every EU brief.

The spot treatment worked perfectly in your lab at 200kg — can we just skip the 20kg intermediate step to save time?
A: That’s exactly the logic that cost Brand X six weeks. The azelaic acid crystallisation failure was invisible at 2kg and catastrophic at 200kg. For formulas with poorly soluble actives, the intermediate step isn’t optional — it’s how you find the problem before it costs real money.

How do you handle the nicotinamide conversion issue with niacinamide at higher pH?
A: Niacinamide hydrolyses to nicotinic acid above pH 6.5, which causes flushing in some consumers. We target pH 5.5–6.0 for niacinamide-containing formulas, and we verify conversion rate as part of our internal stability protocol. Any supplier claiming niacinamide is stable at pH 7.0 in a heated system — we’d want to see their data, not take it on faith.

What’s a realistic MOQ for a 6-SKU launch range, and when does unit cost start making sense?
A: For a liquid or gel acne range, our standard MOQ runs 3,000–5,000 units per SKU depending on formula complexity. Unit economics start looking reasonable for most brand P&Ls around 8,000 units per SKU, which is what we recommended to Brand X. Below 3,000 units, the batch setup cost starts distorting your cost-per-unit significantly.

Should we test for comedogenicity on every SKU, or just the moisturizer?
A: The moisturizer is the obvious one, but the cleanser matters more than most brands think — residual surfactant from a poorly rinsed foaming cleanser can contribute more to pore congestion than the leave-on moisturizer. Our recommendation: comedogenicity risk screening on every leave-on and on the cleanser formulation, especially if you’re targeting an acne-prone consumer who may rinse less thoroughly than your usage instructions assume. The NMPA Cosmetic Regulation also has specific expectations around comedogenicity claims if you’re filing for the China market.

---

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.